Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2356 to 2370 of 7683 results

  1. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  2. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    Awaiting development [GID-TA11468] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer TS ID 12068

    Awaiting development [GID-TA11599] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Artificial intelligence software to help detect and characterise colorectal polyps

    In development [GID-DG10118] Expected publication date: TBC

    Diagnostics guidance
    In development

  8. NVK-002 for treating myopia in people 3 to 17 years TSID 11961

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  10. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

    In development [GID-TA11437] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Acne

    Awaiting development [GID-QS10036] Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Primary hyperparathyroidism

    Awaiting development [GID-QS10089] Expected publication date: TBC

    Quality standard
    Awaiting development

  13. School-based interventions: physical and mental health and wellbeing promotion

    In development [GID-QS10070] Expected publication date: TBC

    Quality standard
    In development

  14. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: 23 April 2025

    Technology appraisal guidance
    In development

  15. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development [GID-TA11091] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development